Home > News > Hashimoto’s Thyroiditis in Adolescents
Thyroid Disorders
Read Time: 6 mins

Hashimoto’s Thyroiditis in Adolescents

Published Online: October 29th 2015 US Endocrinology 2015;11(2):85–8 DOI: http://doi.org/10.17925/USE.2015.11.02.85
Authors: Liliana R Santos, Paulo Fonseca, Paula Soares
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Hashimoto’s thyroiditis (HT) is the most common cause of hypothyroidism in adolescence and mainly affects females. Being the archetype of an organ-specific T-cell-mediated disease, it is characterized by lymphocytic infiltration of the thyroid gland, damage to the thyroid follicular cells, and impaired ability to produce thyroid hormones. It may be associated with other autoimmune diseases and may arise in the context of congenital chromosomal aberrations. Symptoms of hypothyroidism develop insidiously. In adolescents the most common manifestation is the increase of the glandular volume. Hypothyroidism manifestations (asthenia, intolerance to cold, constipation, and/or skin and dry hair) are less common. The diagnosis is based on the presence of thyroid antibodies and characteristic imaging abnormalities on thyroid ultrasound. The treatment relies on the administration of synthetic thyroid hormones for patients with overt hypothyroidism or subclinical hypothyroidism and significant goiter.

Keywords

Hashimoto’s thyroiditis, adolescents, antibodies, hypothyroidism

Article:

The autoimmune thyroid diseases (AITD) comprise a series of interrelated conditions including Graves’ disease (GD) and Hashimoto’s thyroiditis (HT). AITD are the most prevalent diseases of the thyroid gland in the pediatric population, particularly in adolescence.1

HT is the leading cause of goiter and hypothyroidism in children and adolescents in countries with adequate iodine supplementation.2–3 In an American population aged between 11 and 18 years, five new cases were detected out of 1,000 adolescents screened every year.4 It is a much more common condition in females than in males: 4:1 to 8:1 depending on the geographic region.4–6

In the last decade, discoveries in molecular biology field have allowed new insight into the genes involved in the development of AITD. At least six susceptibility genes whose variants have been associated with AITD were identified: HLA-DR, CD40, CTLA-4, PTPN22, thyroglobulin (Tg), and thyroid stimulating hormone (TSH) receptor.7 Genetic susceptibility accounts for 70 % risk for disease that, once combined with environmental factors,

play a crucial role in the initiation and progression of the disease.8 Studies with immunoglobulin (Ig)-G4 autoantibody levels in juvenile thyroid disease patients showed evidence of heritability.9

Etiology
HT etiology is multifactorial. The susceptibility to the disease is determined by an interaction between genetic, environmental, and endogenous factors.10,11 Genetic susceptibility is well evidenced by studies of monozygotic and dizygotic twins where the concordance rate for HT is around 38 % for monozygotic and 0 % for dizygotic twins.12 Although genetic factors play a crucial role in the development of HT, nongenetic factors (environmental) are also involved. In immigrant populations from countries with a low incidence of diseases, this population adopts the new country’s incidence rate.13

Strong evidence suggests iodine as the most significant environmental factor in the generation of thyroiditis. In fact, the prevalence of AITD increase in certain geographical regions, such as Japan and the US, and correlates with iodine intake.14 The concentration of iodine in the thyroid


is about 20 to 40 times higher than in the blood, since this element is essential to the synthesis of thyroid hormones. The process consists of the incorporation of iodine into tyrosine residues of Tg, leading to formation of derivatives of mono- and di-iodotyrosine, which subsequently undergo oxidation resulting in the production of the hormones T3 and T4.15 Several studies suggest that the Tg iodization is crucial for recognition by the T cells and, on the other hand, the excess of iodine may affect the Tg molecule directly, by creating new epitopes or exposing cryptic epitopes.16

Pathogenesis
In the original description in 1912, Hashimoto described the histopathologic features of four thyroids with increased volume and a set of common histologic changes. These histologic changes included fibrosis, increasing number of oxyphilic cells (Hürthle), and diffuse lymphocytic infiltration, in which lymphocytes were organized in true lymphoid follicles with germinal centers, designating these changes as lymphoid transformation of thyroid or “goiter linfoadenomatoso.”17

There is no evidence that the ethiopathogenic mechanisms of HT in children and adolescents differs from those activated in adulthood. The currently accepted mechanism of pathogenesis of HT involves three stages. In the early phase, antigen presenting cells (APC), mainly dendritic cells and macrophages, infiltrate the thyroid gland (for details see Figure 1) The infiltration may be induced by an environmental factor (iodine, toxins, infectious agent), which causes cell damage and the exposure of thyrocytes specific proteins. These proteins serve as their own source of antigenic peptides that are presented on the cell surface of APC after processing. Thyroid APC migrate to the lymph node where interactions occur between the APC cells, activated T cells, and B cells, leading to the induction of a variety of autoantibodies against thyroid-specific antigens.

In the next step, B lymphocytes, cytotoxic T cells, and macrophages infiltrate the thyroid. In this phase there is a clonal expansion of lymphocytes and propagation of lymphoid tissue in the thyroid gland.17,18

In the final stage, “autoreactive” T cells, B cells, and antibodies cause a massive destruction of the thyrocytes. In addition to cell-mediated immune mechanisms, HT is characterized by the production of antibodies against a variety of thyroid-specific antigens, such as thyroglobulin (TG) and peroxidase (TPO), but also the TSH receptor, sodium/iodine (NIS) symporter,19 and pendrin has been recently reported.20

Hashimoto’s Thyroiditis Disease Associations
HT in childhood and adolescence may appear combined with specific autoimmune diseases, namely autoimmune polyglandular syndrome (APS) 1 and 2 (see Table 1). APS-1, which is presented in the first decade of life, is caused by a mutation of a single gene (autosomal recessive defect in AIRE gene mapped to 21q22.3) and is characterized by the development of sequential mucocutaneous candidiasis, hypoparathyroidism, adrenal deficiency, and HT.21 APS-2 tends to occur in the period of later childhood or adolescence, with Addison’s disease in association with HT (Schmidt’s syndrome) or AIT with DM1 (Carpenter syndrome).22 Patients with a particular human leukocyte antigen genotype (HLA-DQ2, HLA-DQ8, and HLA-DR4) are at a higher risk for developing APS-2. The HT was also described in children with immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX syndrome), a polyglandular alteration characterized by early onset diabetes and colitis, linked to the dysfunction of the transcription factor FOXP3.23 HT can coexist with other organ-specific autoimmune diseases, particularly diabetes mellitus type 1. There is a greater incidence of HT in patients with certain chromosomal alterations such as Down syndrome,24 Turner syndrome,25 and Klinefelter syndrome. The AITD may also be associated with chronic urticaria26 and, rarely, glomerulonephritis.27

Clinical Manifestations
Thyroid hormones play an important role in childhood growth and are involved in the maturation and metabolism of certain organs such as the skeleton and brain where they influence the process of myelination of the nervous system.28 One of the biggest differences between HT presentation in childhood and adults remains in the fact that HT hypothyroidism may lead to short stature, decline in school performance, and retardation of development, which have effects in adult life.29 Weak linear growth without apparent cause is a classic initial finding in many children with hypothyroidism. Short stature, with a tendency for overweight becomes evident after months or years of hypothyroidism. The majority are teenagers, clinically euthyroid and asymptomatic, but many present hypothyroidism symptoms and others, despite clinically euthyroid, have laboratorial evidence of hypothyroidism.

Typically, autoimmune thyroiditis is diagnosed in euthyroid patients based on the presence of autoantibodies, goiter or a progressive deficiency in thyroid hormones production and hypothyroidism’s symptoms. Rarely, patients may experience pain in the thyroid region, as well as compression of the trachea or esophagus. Some patients may present multinodular goiter or more rarely, may present an isolated nodule. Usually it is not associated with cervical lymphadenopathy.

In cases of thyroiditis associated with fibrotic gland, teenagers may show a short stature, decreased growth rate, or delayed bone age despite goiter absence.30 The clinical picture of HT in the adolescent population usually has an insidious presentation. In childhood, HT presents with goiter, symmetrical and painless (present in about two-thirds of all cases) or changes of growth. The clinical manifestations of hypothyroidism in adults are lethargy, cold intolerance, constipation, dry hair and/or periorbital edema. The children and adolescents with hypothyroidism tend to have a delayed puberty, but may also induce pseudoprecocious puberty, manifested as testicular enlargement in boys, breast development, and/or vaginal bleeding in girls. This syndrome clinically differs from true precocity by the absence of accelerated bone maturation and linear growth.31 Males normally have an increased testicular volume and rising levels of prolactin and TSH. Several authors consider the possibility of association between pseudopuberty and hypothyroidism due to cross-reactivity between high TSH and FSH receptors.32 The female adolescent may experience an associated precocious puberty and/or polycystic ovaries.33 Some adolescents may have clinical manifestations characteristic of hyperthyroidism such as nervousness, irritability, sweating, behavioral hyperactivity, without laboratory evidence of hyperthyroidism.34

Diagnosis
The determination of serum TSH concentration is the best screening test for primary hypothyroidism. If the TSH is high, the assessment of the serum free thyroxine (fT4) concentration will tell if the child has subclinical hypothyroidism (normal fT4) or hypothyroidism (low fT4). Diagnosis also includes positivity for anti-TPO autoantibodies and/or anti- Tg autoantibodies, accompanied by alteration of thyroid gland and clinical data of thyroid gland volume or sonographic changes of glandular structure.

Echographically thyroid gland presents a heterogeneous and hypoechogenic pattern. The hypoecogenicity is correlated with the intensity of lymphocytic infiltration, levels of circulating antibodies and the severity of hypothyroidism.35,36

Treatment
Most patients with Hashimoto’s thyroiditis are asymptomatic. The replacement hormone therapy is recommended for all patients with TSH

values >10 IU/mL or with TSH values >5 IU/mL in combination with goiter or thyroid autoantibodies.36 In patients with AIT-induced hypothyroidism need an average dose of 1.5 μg/kg per day (≥6 to <10 years: 2.0 μg T4/ kg per day; ≥10 to <12 years: 1.6 μg T4/kg per day; ≥12 to <14 years: 1.5 μg T4/kg per day; ≥14 years: 1.4 μg T4/kg per day). Oral administration of levothyroxine (2–4 μg/kg/day) once daily is a therapeutic option. The normalization of TSH (0.5–2 microIU/mL) is the aim of replacement therapy. Thyroid function tests should be obtained every 6–8 weeks to stabilize the TSH value within the desired range.31 The levothyroxine doses may need to be adjusted depending on the laboratory variations, in order to avoid the onset of symptoms of overdose as agitation, insomnia, flushing, diarrhoea, sweating, or tachycardia.33 Since the biochemical euthyroid status is reached, TSH should be monitored every 4–6 months in children and adolescents.

Levothyroxine should be administered at least 20 minutes before eating or drinking any medication, since it interferes with the absorption of calcium and iron as well as the potassium exchange, aluminium-containing antiacids, bile acid resins linker.

Surgical therapy (thyroidectomy) is recommended only in cases of suspected malignancy coexistence or to relieve compressive symptoms (dysphagia, cough, dyspnea, hoarseness) in patients with large goiters.37

The treatment of children and adolescents with subclinical hypothyroidism (normal fT4, high TSH) is controversial. The long-term follow-up studies of children with subclinical hypothyroidism due to AIT suggested a significant likelihood of remission. Consequently, if there is a strong family history of hypothyroidism and if the patient is not symptomatic, a reasonable option is to re-evaluate thyroid function every 6 months.

Conclusion
Adolescents who display thyroid enlargement should always be evaluated for HT and thyroid function. Although most children with HT remain euthyroid during their lives, thyroid function should be monitored periodically for early detection and treatment hypothyroidism.

Article Information:
Disclosure

Liliana R Santos, BSc, MD, Paulo Fonseca, MD, Rita Cardoso, MD, and Paula Soares, PhD, have no conflicts of interest to declare. No funding was received for the publication of this article.

Correspondence

Paula Soares, PhD, Institute of Molecular Pathology and Immunology of the University of Porto, Rua Dr Roberto Frias s/n, 4200-465 Porto, Portugal.
E: psoares@ipatimup.pt

Support

This research was supported by the Portuguese Foundation for Science and Technology. Further funding was obtained from the project “Microenvironment, metabolism and cancer” that was partially supported by Programa Operacional Regional do Norte (ON.2 – O Novo Norte) under the Quadro de Referência Estratégico Nacional (QREN) and the Fundo Europeu de Desenvolvimento Regional (FEDER IPATIMUP integrates the i3S Research Unit, which is partially supported by FCT, the Portuguese Foundation for Science and Technology. This work is funded by FEDER funds through the Operational Programme for Competitiveness Factors – COMPETE and National Funds through the FCT, under the projects “PEst-C/SAU/LA0003/2013.”

Open Access

This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and
reproduction provided the original author(s) and source are given appropriate credit.

Received

2015-08-11T00:00:00

References

1. Foley TP JR, Abbassi V, Copeland KC, Draznin MB, Brief report: hypothyroidism caused by chronic autoimmune thyroiditis in very young infants, N Engl J Med, 1994;330:466–8.
2. Foley T, Malvaulx P, Blizzard R. Thyroid disease. In: Kappy MS, Blizzard RM, Migeon CJ (editors), The diagnosis and treatment of endocrine disorders in childhood and adolescence. 4th ed. Springfield, IL: Charles C Thomas, 1994;457–533.
3. Skalar CA, Qasi R, David R, Juvenile autoimmune thryroitis, Am J Dis Child, 1986;140:877–80.
4. Setian NS, Hypothyroidism in children: diagnosis and treatment, Jornal Ped, 2007;83:209–16.
5. Hunter I, Greene AS, Macdonald TM, Morris AD, Prevalence and aetiology of hypothyroidism in the young, Arc Dis Child, 2000 2000;83:207–10.
6. De Vries L, Bulvik S, Phillip M, Chronic autoimmune thyroiditis in children and adolescents:at presentation and during long term follow-up, Arch Dis Child, 2009;94:33–7.
7. Yaron T, Armanda H, The etiology of autoimmune thyroid disease: A story of genes and environment, J Autoimmun, 2009;32:231–9.
8. De Lisa Fairweather, Autoimmune disease: mechanisms, Encyclopedia of Life Sciences, 2007;1–6.
9. Outschoorn IM, Talor MV, Bureck CL, et al., Heritability analysis of IIgG4 antibodies in autoimmune thyroid disease, Autoimmunity, 2014;47:320–6.
10. Weetman AP, New aspects of thyroid autoimmunity, Horm Res, 1997;48(Suppl. 4):51–4.
11. Weetman AP, Autoimmune thyroid disease: propagation and progression, Eur J Endocrinol, 2003;148:1–9.
12. Brix TH, Kevin TH, Kyvik KO, Kegedus L, A population-based study of chronic autoimmune hypothyroidism in Danish twins, J Clin Endocrinol Metab, 2003;85:536–9.
13. Prummel MF, Strieder T, Wiersinga WM, The environment and autoimmune thyroid diseases, Eur J Endocrinol, 2004;150:605–18
14. Duron F, Dubosclard E, Johanet C, Thyroiditis, EMC Endocrinologie, 2004;3–18.
15. Zang J, Lazar MA, The mechanism of action of thyroid hormones, Annu Rev Physiol, 2000;62:439–66.
16. Parish NM, Cooke A, Mechanisms of autoimmune thyroid disease, Drug Discov Today, 2004;1:337–44.
17. Pearce EN, Farwell AP, Braverman LE, Thyroiditis, N Engl J Med, 2003;348:2646–55.
18. Yoshida A, Hisatome I, Taniguchi S, et al., Pendrin is a novel autoantigen recognized by patients with autoimmune thyroid diseases, J Clin Endocrinol Metab, 2009;94:442–8.
19. Weetman AP, Cellular immune responses in autoimmune thyroid disease, Clin Endocrinol (Oxf), 2004;61:405–13.
20. Ajjan RA, Kemp EH, Waterman EA, et al., Detection of binding and blocking autoantibodies to the human sodium-iodide symporter in patients with autoimmune thyroid disease, J Clin Endocrinol Metab, 2000;85:2020–7.
21. Betterle C, Greggio NA, Volpato M, Autoimmune polyglandular syndrome type 1, J Clin Endocrinol Metab, 1998;83:1049–55.
22. Eisenbarth GS, Gottlieb PA, Autoimmune polyendocrine syndromes, N Engl J Med, 2004;350:2068–79.
23. Wildin R, Smyk-Pearson S, Filipovich A, Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome, J Med Genet, 2002;39:537–45.
24. Karlsson B, Gustafsson J, Hedov G, et al., Thyroid dysfunction in Down’s syndrome: relation to age and thyroid autoimmunity, Arch Dis Child, 1998;79:242–5.
25. Elsheikh M, Wass JA, Conway GS, Autoimmune thyroid syndrome in women with Turner’s syndrome-the association with karyotype, Clin Endocrinol (Oxf), 2001;55:223–6.
26. Verneuil L, Leconte C, Ballet JJ, et al., Association between chronic urticaria and thyroid autoimmunity: a prospective study involving 99 patients, Dermatology, 2004;208:98–1.
27. Gurkan S, Dikman S, Saland MJ, A case of autoimmune thyroiditis and membranoproliferative glomerulonephritis. Pediatr Nephrol, 2009;24:193–7.
28. Larsen PR, Davis TF, Hay ID, The thyroid gland. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds, Williams Textbook of Endocrinology, Philadelphia: Saunders, 1998:389–515.
29. Radetti G, Gottardi E, Bona G, et al.; Study Group for Thyroid Diseases of the Italian Society for Pediatric Endocrinology and Diabetes (SIEDP/ISPED), The natural history of euthyroid Hashimoto’s thyroiditis in children, J Pediatr, 2006;149:827–32.
30. Setian N, Hypothyroidism in children:diagnosis and treatment, Jornal Ped, 2007;83:209–16.
31. Anasti JN, Flack MR, Froehlick J, et al.,A potential novel mechanism for precocious puberty in juvenile hypothyroidism, J Clin Endocrinol Metab, 1995;80:276–9.
32. Bongers-Schokking JJ, De Muinck Keiser-Schrama SM, Influence of timing and dose of thyroid hormone replacement on mental psychomotor, and behavioral development in children with congenital hypothyroidism, J Pediatr, 2005;147:768–74.
33. Lamberton P, Jackson I, Thyroiditis. In: Bremmer WJ, Hung W, Kann CR, et al., Principles and Practice of Endocrinology and Metabolism. 1a edition, Philadelphia, PA: JB Lippincott Company, 1990;370–7.
34. Slatosky J, Shipton B, Wahba H, Thyroiditis: differential diagnosis and management, Am Fam Physician, 2000;61:1047–52. 35. Mandel SJ, Brent GA, Larsen PR,Levothyroxine therapy in patients with thyroid disease, Ann Intern Med, 1993;119:492–502.
36. Lee HS, Hwang S, The natural course of Hashimoto’s thyroiditis in children and adolescents, J Pediatr Endocr Met, 2014;27:807–12.
37. Shih ML, Lee JA, Hsieh CB, Yuet al. Thyroidectomy for Hashimoto’s thyroiditis: complications and associated cancers. Thyroid, 2008;18:729–34.
38. Arscott PL, Baker JR Jr, Apoptosis and thyroiditis, Clin Immunol Immunopathol, 1998;87:207–17.

Further Resources

Share this Article
Related Content In Thyroid Disorders
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72